The authors review the application of ideal histone deacetylases 2 (HDAC2) inhibitors with solid anti-tumor efficacy in combination with immunotherapy for HCC.
[Cancer Cell International]
Home Newsletters Hepatic Cell News Enhancing HCC Treatment: Innovatively Combining HDAC2 Inhibitor with PD-1/PD-L1 Inhibition
